» Articles » PMID: 36831649

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 25
PMID 36831649
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) in the setting of non-alcoholic fatty liver disease (NAFLD)-related cirrhosis and even in the pre-cirrhotic state is increasing in incidence. NAFLD-related HCC has a poor clinical outcome as it is often advanced at diagnosis due to late diagnosis and systemic treatment response is poor due to reduced immune surveillance. Much of the focus of molecular research has been on the pathological changes in hepatocytes; however, immune cells, hepatic stellate cells, liver sinusoidal endothelial cells and the extracellular matrix may play important roles in the pathogenesis of NAFLD-related HCC as well. Here, we review the role of non-parenchymal cells in the liver in the pathogenesis of HCC in the context of NAFLD-NASH, with a particular focus on the innate and the adaptive immune system, fibrogenesis and angiogenesis. We review the key roles of macrophages, hepatic stellate cells (HSCs), T cells, natural killer (NK) cells, NKT cells and liver sinusoidal endothelial cells (LSECs) and the role of the extracellular matrix in hepatocarcinogenesis within the steatotic milieu.

Citing Articles

From MASLD to HCC: What's in the middle?.

Provera A, Vecchio C, Sheferaw A, Stoppa I, Pantham D, Dianzani U Heliyon. 2024; 10(15):e35338.

PMID: 39170248 PMC: 11336632. DOI: 10.1016/j.heliyon.2024.e35338.


The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.

Hu N, Li H, Tao C, Xiao T, Rong W Int J Mol Sci. 2024; 25(11).

PMID: 38891772 PMC: 11171976. DOI: 10.3390/ijms25115584.


Diagnostic value of triglyceride-glucose index and related parameters in metabolism-associated fatty liver disease in a Chinese population: a cross-sectional study.

Yu R, Xie W, Peng H, Lu L, Yin S, Xu S BMJ Open. 2023; 13(9):e075413.

PMID: 37775293 PMC: 10546149. DOI: 10.1136/bmjopen-2023-075413.


Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis.

Kakehashi A, Suzuki S, Wanibuchi H Cancers (Basel). 2023; 15(18).

PMID: 37760534 PMC: 10527326. DOI: 10.3390/cancers15184566.


Customized liver organoids as an advanced modeling and drug discovery platform for non-alcoholic fatty liver diseases.

Han D, Xu K, Jin Z, Xu Y, Li Y, Wang L Int J Biol Sci. 2023; 19(11):3595-3613.

PMID: 37497008 PMC: 10367556. DOI: 10.7150/ijbs.85145.


References
1.
Cha J, Kim D, Chun K . The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Lab Anim Res. 2019; 34(4):133-139. PMC: 6333604. DOI: 10.5625/lar.2018.34.4.133. View

2.
Dewidar B, Meyer C, Dooley S, Meindl-Beinker A . TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019; 8(11). PMC: 6912224. DOI: 10.3390/cells8111419. View

3.
Kent G, Gay S, Inouye T, Bahu R, Minick O, Popper H . Vitamin A-containing lipocytes and formation of type III collagen in liver injury. Proc Natl Acad Sci U S A. 1976; 73(10):3719-22. PMC: 431190. DOI: 10.1073/pnas.73.10.3719. View

4.
Chung A, Mettlen M, Ganguly D, Lu T, Wang T, Brekken R . Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2020; 13(11):911-922. PMC: 8284815. DOI: 10.1158/1940-6207.CAPR-20-0200. View

5.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View